We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Top Research Reports for Wells Fargo, Accenture & Eli Lilly
Read MoreHide Full Article
Monday, January 16 2017
Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC - Free Report) , Accenture (ACN - Free Report) and Eli Lilly (LLY - Free Report) . We also issued an early take on the Q4 earnings season, which ramps up materially in the coming days. The earnings report is titled: Solid Start to Q4 Earnings Season
Wells Fargo shares have gained 24.3% over the last three months, underperforming the Zacks Major Banks industry which has gained 28.9% over the same period. The bank has yet to fully recover from the scandal even after a $190-million settlement with regulators, but the company’s fourth-quarter 2016 earnings outpaced estimates and prior-year quarter’s earnings. The new management team is making all the right moves and further downside risks in the stock are low at this stage. But it will likely take a while for clouds to be fully lifted, though continued growth in loans and deposits and expansion moves should support its growth profile (You can read the full research report on Wells Fargo here >>)
Accenture shares have performed in line with the consulting industry over the last one year, gaining 17.8%. The company delivered mixed first-quarter fiscal 2017 results, though revenues and earnings were up on a year-over-year basis. The analyst likes the company’s inorganic growth strategy. This has enabled Accenture to broaden its product portfolio and is likely to contribute significantly to its revenues stream. However, increasing competition and an uncertain macroeconomic environment may deter its growth to some extent (You can read the full research report on Accenture here >>)
Eli Lilly shares were under pressure in 2016 but have recovered this year, gaining 5.2% to outperform other large cap pharma stocks. Estimates have moved up lately ahead of the company’s Q4 release. The analyst is encouraged by the fact that Lilly expects to launch 20 new products in a 10 year time-frame ranging from 2014 to 2023 and could launch at least 2 new indications/line extensions on average every year. Moreover, Lilly returned to annual dividend increases in Dec 2016 and has issued a bullish outlook for 2017. (You can read the full research report on Eli Lilly here >>)
Other noteworthy reports we are featuring today include American Airlines (AAL - Free Report) , PNC Financial (PNC - Free Report) and Domino’s Pizza (DPZ - Free Report) .
Today's Long-Term Buys & Sells Today you can gain access to the best long-term trades unearthed by Zacks Research. These moves have double and triple-digit profit potential and are rarely available to the public. Starting now, you can look inside our stocks under $10, home run and value stock portfolios, plus more. Want a peek at this private information? Click here >>
Sheraz Mian
Director of Research
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here >>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Top Research Reports for Wells Fargo, Accenture & Eli Lilly
Monday, January 16 2017
Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC - Free Report) , Accenture (ACN - Free Report) and Eli Lilly (LLY - Free Report) . We also issued an early take on the Q4 earnings season, which ramps up materially in the coming days. The earnings report is titled: Solid Start to Q4 Earnings Season
Wells Fargo shares have gained 24.3% over the last three months, underperforming the Zacks Major Banks industry which has gained 28.9% over the same period. The bank has yet to fully recover from the scandal even after a $190-million settlement with regulators, but the company’s fourth-quarter 2016 earnings outpaced estimates and prior-year quarter’s earnings. The new management team is making all the right moves and further downside risks in the stock are low at this stage. But it will likely take a while for clouds to be fully lifted, though continued growth in loans and deposits and expansion moves should support its growth profile (You can read the full research report on Wells Fargo here >>)
Accenture shares have performed in line with the consulting industry over the last one year, gaining 17.8%. The company delivered mixed first-quarter fiscal 2017 results, though revenues and earnings were up on a year-over-year basis. The analyst likes the company’s inorganic growth strategy. This has enabled Accenture to broaden its product portfolio and is likely to contribute significantly to its revenues stream. However, increasing competition and an uncertain macroeconomic environment may deter its growth to some extent (You can read the full research report on Accenture here >>)
Eli Lilly shares were under pressure in 2016 but have recovered this year, gaining 5.2% to outperform other large cap pharma stocks. Estimates have moved up lately ahead of the company’s Q4 release. The analyst is encouraged by the fact that Lilly expects to launch 20 new products in a 10 year time-frame ranging from 2014 to 2023 and could launch at least 2 new indications/line extensions on average every year. Moreover, Lilly returned to annual dividend increases in Dec 2016 and has issued a bullish outlook for 2017. (You can read the full research report on Eli Lilly here >>)
Other noteworthy reports we are featuring today include American Airlines (AAL - Free Report) , PNC Financial (PNC - Free Report) and Domino’s Pizza (DPZ - Free Report) .
Today's Long-Term Buys & Sells
Today you can gain access to the best long-term trades unearthed by Zacks Research. These moves have double and triple-digit profit potential and are rarely available to the public. Starting now, you can look inside our stocks under $10, home run and value stock portfolios, plus more. Want a peek at this private information? Click here >>
Sheraz Mian
Director of Research
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here >>>